Discrepancies between payer coverage and consensus guidelines for personalizing hereditary cancer risk

Comparison of HBOC genetic testing policies from three US insurers to NCCN v2.2019 medical management guidelines available for 16 genes identified that among insurers A, B, and C, 6(37.5%), 8(50.0%) and 15(93.8%) of the genes were covered, respectively.
On a patient level, limiting genetic testing to payer coverage resulted in unidentified mutations and missed opportunities to personalize cancer risk management in accordance with expert consensus.
This data supports the expansion of insurer genetic testing policies to include MGPT for patients at high-risk of HBOC.

Authors: Jill Dolinsky; Lily Hoang; Patrick Reineke; Nancy Niguidula; Victoria Ellis; Emily Dalton; Jessica Profato; Greg Nogle; Holly LaDuca
Conference: ASBrS 2019
Date: Friday, May 03, 2019 6:00pm - 7:30pm

Download Poster

View All Scientific Posters

Search Results